Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays

Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays

Abstract Background Amyloid-β 1–42 (Aβ1–42) peptide is a well-established cerebrospinal fluid (CSF) biomarker for Alzheimer’s disease (AD). Reduced levels of Aβ1–42 are indicative of AD, but significant variation in the absolute concentrations of this analyte has been described for both healthy and...

Full description

Bibliographic Details
Main Authors: Stephen P. Schauer, William R. Mylott, Moucun Yuan, Rand G. Jenkins, W. Rodney Mathews, Lee A. Honigberg, Kristin R. Wildsmith
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Adsorption
Biomarkers
Cerebrospinal fluid
Amyloid-β
Preanalytical
Online Access:http://link.springer.com/article/10.1186/s13195-018-0445-0

Internet

http://link.springer.com/article/10.1186/s13195-018-0445-0

Similar Items